Icagen, Inc. Announces Presentations Related To Senicapoc At The 2006 Annual Meeting Of The American Society of Hematology
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Icagen, Inc. (NASDAQ: ICGN) today announced that materials related to its clinical development program of senicapoc, a novel inhibitor of the Gardos ion channel, for the treatment of sickle cell disease were recently presented at the 2006 annual meeting of the American Society of Hematology in Orlando, Florida.